ISTH 2022 Congress
Hemophilia and Rare Bleeding Disorders » Acquired Hemorrhagic Coagulation Disorders
Theme Navigation
- ISTH 2022 Congress
- Hemophilia and Rare Bleeding Disorders
- Acquired Hemorrhagic Coagulation Disorders
- Hemophilia and Rare Bleeding Disorders
-
Abstract Number: PO0029
Acquired Hemophilia A: case report
-
Abstract Number: PB0168
Acquired Hemophilia in four north European countries, a survey of 181 patients
-
Abstract Number: PB1431
Acquired von Willebrand syndrome in essential thrombocythemia patients referred to special coagulation laboratory of Iranian Blood Transfusion Organization (IBTO)
-
Abstract Number: VPB0170
Correlation of Factor VIII Activity Measured by One-Stage Clotting and Chromogenic Substrate Assays in a Phase III Study of Emicizumab Prophylaxis for Acquired Hemophilia A (AGEHA)
-
Abstract Number: OC 63.5
Cytokine profile of patients with Acquired Hemophilia A (AHA) in a longitudinal study
-
Abstract Number: OC 40.2
Efficacy, Safety, and Pharmacokinetics of Emicizumab Prophylaxis in Patients with Acquired Hemophilia A: Primary Analysis Results from a Phase III Study (AGEHA)
-
Abstract Number: PB0167
Emicizumab use in Acquired von Willebrand Disease: Single Case Report
-
Abstract Number: PB0166
Five cases of Acquired Haemophilia A (AHA) following COVID-19 vaccination in Australia
-
Abstract Number: PB0169
Proof of principle of a fast and fully automated FVIII functional inhibitor test